Last reviewed · How we verify
NCT04725058
Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting
NA trial testing Medical Group Visit in Obesity in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.
28 December 2025
Quick facts
| Lead sponsor | Charles Drew University of Medicine and Science |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 1,000 |
| Start date | 3 February 2020 |
| Primary completion | 28 December 2025 |
| Estimated completion | 28 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Medical Group Visit
- Dietitian Individual Visit
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Charles Drew University of Medicine and Science
Who can join
Adults 18 to 90, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study has two aims: Aim 1: To compare a medical group visit model versus a dietitian-let model (shared composite group visit approach vs individualized dietitian-led approach) to provide obesity care in a real-world diverse inner city population. Aim 2. To use both perivascular fat attenuation and coronary artery calcium (CAC) scores in those receiving composite group intervention vs. dietitian-led intervention to see if lifestyle intervention can reduce plaque progression and improve perivascular fat attenuation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04725058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Charles Drew University of Medicine and Science trials
Trials by the same sponsor.
- NCT06075732 — ACTIVATE in Public Housing · NA · completed
- NCT05605028 — A Mental Health Intervention for a Community Program Called the PowerObesity · NA · withdrawn
- NCT04542395 — COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents · NA · withdrawn
- NCT05805306 — Entre Herman@s: Promoting Health Among Latino MSM · NA · completed
- NCT05471141 — Preventing and Managing Cognitive Impairment · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04725058 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charles Drew University of Medicine and Science
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04725058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing